Press Release April 26, 2018

Corvidia Therapeutics Secures $60 Million in Series B Financing Round

The Life Sciences team advised Corvidia Therapeutics as it closed a $60 million Series B financing round to accelerate the growth of its ongoing clinical programs, expand scientific and market access capabilities, and explore new treatment areas. The financing will also be used to progress its lead clinical programs in chronic kidney disease as well as advance its pre-clinical programs.

Venrock led the Series B financing and was joined by five additional new investors: Andera (formerly Edmond de Rothschild), Cormorant Asset Management, HBM Healthcare Investments, Fresenius Medical Care Ventures GmbH and Venrock Healthcare Capital Partners (VHCP). Series A investors Apple Tree Partners, MedImmune, the global biologics research and development arm of AstraZeneca, and Sofinnova Partners, the founding seed investor, also participated in this round.

Corvidia Therapeutics is a clinical stage biotechnology company based in Waltham, Massachusetts pioneering the next generation of cardiovascular and cardio-renal therapies.

The Goodwin team was led by partner Kingsley Taft and included associates Yasin Akbari, Noelle Dubiansky and Thomas Murphy.

For additional details on the financing, please read the press release.